ArticlePloS one2025

Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US.

Ping Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.